The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The share price has dwindled. Agree must be down to funding. However I would hope OCTP would have not just made the appointment if they thought they were not going to get funding moving forward to stage 2. I expect we as shareholders will take a hit in the next funding as in these early development companies we always seem to.
Always the same how a couple of hundred thousand share sells cause a fall in the price yet a six hundred thousand buy doesn’t take it back up. The markets always seem to react so quick to selling pressure compared to buying or so it seems.
Just getting over covid and have had some what appeared to be trigemenal pain which can be a viral symptom. Was awful and not touched by available analgesics. Having read more about trigemenal Neuralgia and the limited available treatment for this miserable condition hopefully if successful our medication can’t come soon enough.
Mr India. The negativity towards the stock is because Hemo so far failed to deliver and confidence was broken. To fall at the last hurdle when it was believed that Hemo had been involved with the FDA to process approval seems poor and thus collapse in confidence. It felt like another Mint moment. It seems that this is the price range while people wait and see if progress is made. I like many have been burned by false dawns and want to see some solid results before committing again.